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Technetium-99m(99mTc) sestamibi (MIBI) was first used as a par
athyroid imaging agent in Hawaii in 1991. The purpose of this study
was to determine the sensitivity and positive predictive value of the
MIBI scan in detecting abnormal parathyroid glands. A retrospec
tive, multi-center study from 1992-1994 involving 33 patients in four
hospitals showed the overall sensitivity of the MIBI scan for detect
ing hyperparathyroid disease was 90%. The positive predictive
value was 93%. It was more sensitive in detecting adenomas (95%)
than hyperplasia (45%). In conclusion, the MIBI scan can be helpful
in detecting abnormal parathyroid glands and may be most useful
prior to reoperations for persistent and recurrent hyperparathyroid
ism.
Introduction
Clinical symptoms of hyperparathyroidism (HPT) are often non
specific, especially early in the disease process. The incidence of
HPT is increasing, with most patients found in an asymptomatic
state by routine screening. The most common causes for this
condition are parathyroid adenomas, hyperplasia, and rarely, neo
plasms. In most cases, the cause of primary HPT is a solitary
adenoma involving one of the parathyroid glands. For patients with
end-stage renal disease (ESRD), the incidence of HPT is increased
over that of the general public, and is almost always due to
hyperplasia of the glands. Neoplasms in the parathyroids are rare,
but do occur. A diagnosis of HPT can often be confirmed by
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elevated serum calcium levels and/or elevated parathyroid hormone
levels. For patients with hyperfunctioning parathyroid glands, sur
gical exploration ofthe neck with removal ofthe suspicious gland(s)
is the definitive treatment. This approach has been shown to be
curative in the majority ofcases, with surgical success rates of90%-
95%1
Anatomically, parathyroid glands may be found anywhere from
beneath the mandible to the level of the pericardium.2They are most
commonly found anteriorly, in the lateral posterior surface of the
lower pole of the thyroid, in the thymic tongue, or lateral to the lower
pole of the thyroid.3Most individuals have four parathyroid glands,
but there are documented cases of supernumerary glands. Ectopic
glands have been located in the thyroid gland, substernal and
mediastinal areas.
Due to variations in anatomical positions where the parathyroid
glands have been found, and the concern that an abnormal number
ofglands may be causing the hypercalcemic condition, preoperative
techniques that reliably locate the parathyroid glands have been
sought after and investigated. A variety of imaging techniques have
been attempted, including non-invasive tests such as ultrasound,
magnetic resonance imaging, computed tomography, and nuclear
medicine scans using a variety of radiotracers,4’5and the more
invasive diagnostic tests such as venous sampling and selected
arteriography. The search for valid and reliable methods has re
cently focused on the use of a radiotracer technetium-99m(99mTc)
sestamibi. This radiotracer, originally marketed for cardiac imag
ing, has been shown to be useful in the preoperative detection and
localization of parathyroid adenomas in patients having proven
hyperparathyroidism.5’6
Available in Hawaii since 1991, the sestamibi (MIBI) scan is
currently the most popular method used preoperatively to localize
the parathyroid glands. During this study period, all four participat
ing hospitals followed a similar procedure that included the use of
a single radiotracer and a “washout” technique.6The purpose of this
study was to determine the sensitivity, specificity, positive and
negative predictive value of the MIBI scan by grouping the data
from four local hospitals.
Methods
Institutional Review Board approval to conduct this medical
record study was obtained from four hospitals in the metropolitan
Honolulu area. These Hospitals were St. Francis Medical Center
Liliha, Queen’s Medical Center, Kuakini Medical Center, and
Straub Clinic and Hospitals, Inc. Due to the geographical proximity
of these hospitals and the patient flow between them, a multi-center
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pooling ofpatients was used to obtain more comprehensive data. To
identify study cases, the Nuclear Medicine Departments at the
above institutions were contacted with a request for the names of
individuals who had undergone a MIBI study of the parathyroid
glands from 1992 to 1994. Using this patient list, inpatient medical
records were reviewed from the respective hospitals.
When reviewing the medical records, if the patient had undergone
aparathyroidectomy, the following information was obtained: pre
operative serum calcium level, surgical procedure performed, num
ber and location of normal and abnormal parathyroid glands, time
from incision to closure for the procedure, any surgical complica
tions, pathology reports, and post-operative serum calcium level on
the day of discharge. Patients who did not undergo surgery were
excluded from the study.
If there was no inpatient medical record at the institution where the
nuclear medicine study was performed, the referring physician’s
office was contacted and asked if the patient had undergone a
parathyroidectomy at any other local hospital. Records were then
reviewed at these hospitals.
Sestamibi Scan
A MIBI scan was performed when HPT was suspected. For this
scan, no specific patient preparation is required. All four participat
ing hospitals used similar, although not identical, imaging tech
niques as described by Taillefer6with early and late MIBI imaging.
With the patient supine and neck extended, anterior images of the
neck and chest were acquired 10-15 minutes and 2-3 hours after
intravenous administration of 20-24 mCi MIBI. Analog images
were acquired with a preset time of 10 minutes using a scintillation
camera with low energy, high resolution or all-purpose parallel hole
collimator. Digital data (128 X 128 matrix) were also acquired
Table 1.—Mathematical Computation for Sensitivity, Specificity,
Positive and Negative Predictive Value.
Hyperparathyroid Disease
MIBI Scan Results Yes No Total
Positive a b a + b
Negative c d c + d
Total a+c b+d
a = True b = False c = False d = True
Positives Positives Negatives Negatives
during 10 minutes. Optional views included imaging with a pinhole
collimator. SPECT (tomography) or use of a second tracer was not
utilized during the time interval for this study. The initial image
obtained at 10-15 minutes after injection of MIBI was used as the
“thyroid” phase of the study and represents the concentration of the
tracer by the thyroid parenchyma. The second image performed
between 2-3 hours after injection corresponded to the delayed or
“parathyroid” phase. Both initial and delayed images of a given
patient were placed side by side for comparison and viewed on
either hardcopy or computer display.
A positive MIBI scan for parathyroid adenoma was defined as an
area of increased focal uptake of the tracer in projection of the
thyroid bed and surrounding areas or mediastinum which showed
either a relative progressive increase over time7 or a fixed uptake
which persisted on delayed imaging (see figure 1). This pattern
differs from uptake in the normal thyroid tissue which progressively
decreases over time (differential washout analysis). This is due to
the fact that the tissue kinetics of the thyroid and hyperactive
parathyroid have substantially different resident times for Tc-99m
sestamibi. The location of the parathyroid usually included the exact
location of the parathyroid: right or left side; upper, lower or ectopic
location. Parathyroid hyperplasia was interpreted only if more than
one abnormal focus was identified on dual-phase MIBI imaging.
Data Analysis
For each patient in this study, the results of the MIBI scan from the
nuclear medicine report, the surgical report and pathology findings
were retrospectively compared to determine the sensitivity and
specificity of the MIBI scan. For a true positive, the scan interpre
tation was the same as the surgical and pathology findings. A false
positive study was when the MIBI scan determined disease, but the
diagnosis did not match the surgical findings, or there was no
parathyroid disease. A false negative study did not show any
abnormality on the scan, while the surgical and pathological reports
showed abnormally enlarged tissue. False negative results were also
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Fig. 1.—Sestamibi Scan Showing Prominant Left Lower Parathyroid






Positive Predictive Value =
ci
Negative Predictive Value
= (c + d)
MIBI Scan Results Adenoma Hyperplasia Normal
Adenoma n=19 n=4 n=2
Hyperplasia n = 0 n = 5 n = 0
Normal n=1 n=2 n=0
True True False False
Positive Negative Positive Negative
Adenoma 19 0 6 1
Hyperplasia 5 0 0 6
Sensitivity for Adenoma 19/20 95%
Positive Predictive Value 19/25 76%
Sensitivity for Hyperplasia 5/11 45%
Positive Predictive Value 5/5 100%
assigned to patients where one type of disease was diagnosed by
MIBI and another type was diagnosed by pathology.
Sensitivity was defined as the number of true positives divided by
the sum of true positives and false negatives. Specificity was
defined as the number of true negatives divided by the sum of true
negatives and false positives. The positive predictive value (PPV)
of the MIBI scan was calculated by dividing the number of true
positives by the sum of true positives and false positives. Negative
predictive value (NPV) was the number of true negatives divided by
the sum of false negatives and true negatives (Table I).
Results
A total of 48 patient names were obtained from the Nuclear
Medicine Departments of the four participating hospitals. Of these
48 patients, 33 underwent surgery on their parathyroid glands, and
the data analysis refers only to this group. There were 22 females
(67%) and 11(33%) males. Average age of patients during the time
of the scan was 50.6 years old (range 21 to 86). Average time from
scan to surgery was 2.2 months (range 1 day to 18 months).
Preoperative serum calcium levels ranged from 9.5 to 12.9 mg/dl
(mean of 11.2 ± 0.78 mg/dl). Three patients had undergone previous
neck exploration. Eight of the patients has a primary diagnosis of
end-stage renal disease and secondary HPT; 25 of the patients had
primary HPT.
MIBI scans preoperatively diagnosed 25 patients with adenomas
and 5 patients with hyperplasia. Three scans were interpreted as
normal. In contrast, operative and pathologic findings confirmed 20
cases of adenoma and 11 cases of hyperplasia. Two cases were
negative for parathyroid disease and resulted in thyroid biopsy or
thyroid goiter removal. In the 3 cases where the M1131 scan was read
as normal, the operative and pathologic findings were positive for
adenoma (1 case) or hyperplasia (2 cases). In 4 cases, the MIBI scan
was positive for parathyroid adenoma, but surgical findings were
positive for hyperplasia (Table 2).
MIBI Scan Results Positive Negative
Positive n = 28 n = 2
Negative n=3 n=O
Sensitivity 28/31 90%
Specificity unable to determine due to no true negatives
Positive Predictive Value 28/30 93%
Negative Predictive Value unable to determine due to no true negatives
Three patients had a history ofprevious neck surgery. One of these
patients had persistent hyperplasia following near-total parathyroid
gland resection for hyperplasia that had occurred 3 years earlier. The
MIBI scan and surgicallpathology results both diagnosed hyperpla
sia. Another patient who was diagnosed with hyperplasia in surgery
had previously undergone a thyroid lobectomy. This patient had
preoperative MIBI scans which were interpreted as adenoma ini
tially, followed by compensatory hypertrophy. The last case in
volved resection of a Wharton’s Tumor six months prior to the MIBI
scan. This scan was interpreted as adenoma, but at surgery only 3
normal parathyroid glands were found.
Overall, the sensitivity of the MIBI scan for HPT disease (not
differentiating adenoma from hyperplasia) was 90%. The positive
predictive value (PPV) was 93% (Table 3). Specificity or negative
predictive value (NPV) based on presence of disease could not be
determined because no true negatives were identified by the study’s
methodology.
When the results were separated into categories of adenoma and
hyperplasia, the sensitivity and PPV changed. The sensitivity of the
MIBI scan for adenoma was 95% (19/20 cases), with a positive
predictive value of 76% (19/25 cases). The sensitivity of the M1131
scan for hyperplasia was 45% (5/11 cases), with a PPV of 100% (5/
5 cases), as shown in Table 2. For all cases, the specificity and NPV
were not determined due to the lack of true negatives (i.e. not all
patients with negative scans underwent surgery to confirm normal
ity).
There were 3 cases where the MIBI scan was interpreted as
normal, but parathyroid disease was confirmed by pathology. In 1
case, an adenoma was found, and in 2 cases, hyperplasia was found.
In 4 cases, hyperplastic parathyroid disease was found at surgery,
but incorrectly identified as adenoma by preoperative MIBI scans.
In the calculations for sensitivity and PPV, these cases were used
both as false positive for adenoma and false negative for hyperpla
sia.
The gland weight of the diseased parathyroids was listed for 28 of
the 33 patients. The average gland size of a parathyroid adenoma
was 1.45 ±1.2 gms (range 0.2 to 4.98 gms, n=18 glands in 18
patients). Hyperplastic glands averaged .55 ± .48 gms (range 0.02
to 1.9 gms, n=34 glands in 10 patients). The difference in gland
weight was significant (p=.OO8,2-tailed t-test).
The sensitivity, specificity, positive and negative predictive value
based on individual glands can be calculated from this data, and are
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Table 2.—Patient Diagnosis Comparing Sestamibi Scan Results &
Actual SurgicallPathology Results.
Actual Surgical Pathology Results
Table 3.—Patient Diagnosis Comparing MIBI Scan Results & Actual
Surgical Confirmation of Disease
Surgical Confirmation of Parathyroid Disease
Table 4.—Comparison of MIBI Scan Results & Actual Pathology Results
by Individual Gland
Pathology Results
MIBI Scan Results Adenoma Hyperplasia Normal*
Adenoma 16 4 5
Hyperplasia 0 18 0
Normal 4 18 19
‘ also includes 2 cases of thyroid disease
True True False False
Positive Negative Positive Negative
Adenoma 16 19 9 4
Hyperplasia 18 19 0 22
shown in Table 4. Although no individuals with normal scans
underwent an operation, glands that were normal on MIBI scan were
biopsied in some cases, and were used as true negatives if the MIBI
report and pathology report were both interpreted as normal.
Postoperative serum calcium ranged from 7.8-11.4 mg/dl (mean
9.09 ± 0.92 mg/dl). Postoperative complications included 7 cases of
hypocalcemia and one case of hoarseness and difficulty swallow
ing. All complications resolved by the time ofdischarge. There were
no reoperations or recurrences noted during this study period.
Discussion
The sensitivity of the MIBI scan has been shown to be equal or
superior to other forms of preoperative imaging of the parathyroid
glands. There are multiple ways this radiotracer is used: as a single
radiotracer in a washout technique as described,6 in combination
with other radiotracers in subtraction studies4’89”°”1,12,13 with intra
operative PTH measurement,’4with factor analysis of dynamic
structures,’5and intraoperatively combined with nuclear medicine
imaging.’6Review of these studies demonstrate a sensitivity range
of 84%-100% for imaging parathyroid adenomas and 55%-100%
for detecting hyperplasia.
The overall sensitivity of the MIBI scan for diagnosing
hyperparathyroid disease was 90% in this study. This supports the
national literature that the MIBI scan was more sensitive in diagnos
ing adenoma (95%) than hyperplasia (45%).
Assignment to categories in this study was strict as reflected in the
sensitivity and specificity. A match between the correct anatomical
position on both MIBI scan and surgical/pathology reports was
required for a true positive reading in Table 3. In all cases, the correct
side of the neck was identified, but there were 6 cases where there
was a difference between quadrant named on scan and surgical/
pathology location of diseased gland. True negatives were only
assigned to pathologically normal glands and this sample was
limited. Unfortunately, the study team was unable to determine the
specificity and NPV in the study as it was designed. There was an
inherent bias because the patients studied presumably had chemical
HPT and were scheduled for surgery (or biopsy) because of symp
tomatology. The specificity in the literature for scintigraphy using
any method in patients without HPT has been reported in the range
of 77-l00%.
As noted in other studies, the sensitivity for detecting adenomas
was much higher than for hyperplasia. While the MIBI scans were
accurate in picking up disease, they were not as accurate in differ
entiating adenoma from hyperplasia. The difference in gland size
may be a factor. The most obvious hazard in this scenario is that the
neck exploration will be stopped after the abnormal gland(s) iden
tified by scan is removed, leaving behind unsuspected hyperplastic
glands that will need to be removed at subsequent surgery.
A proposed benefit to preoperative scanning is a decrease in
operative time.8If the scan clearly documents a single adenoma, the
opposite side may not need to be explored. This benefit, however,
has not been universally supported.’ In this study, the mean operat
ing time from incision to skin closure was 107.7 ± 33.9 minutes
(range 56-185 minutes). A comparison group of patients who had
parathyroid surgery without preoperative MIBI imaging was not
drawn due to the different number of surgeons performing the
operations and the multiple hospitals that were involved in this
study. Thus, whether preoperative imaging can actually decrease
operative time could not be validated from this study data.
Finally, there is controversy over the routine use of the MIBI scan,
debating the benefits to the patient and surgeon versus the expense
of the test, and the true surgical advantage provided by its use
preoperatively. A quote frequently used in this debate is that “the
only localization needed prior to surgery is to locate an experienced
parathyroid surgeon.”5”4Whether these localization tests should be
used in all patients, or reserved for those undergoing repeated
exploration is currently being debated. One side recommends the
use of this scan as a preoperative exam only in cases of reoperation
for persistent or recurring hyperparathyroidism,”5’6”while others
feel that preoperative localization in initial neck operations is
useful. ‘°Concurrent with the debate over patient selection are many
issues regarding technique, to include the optimum imaging proto
col, radiotracers used alone or in combination, and time frames from
dosing to imaging.
Summary
Sestamibi parathyroid imaging is relatively new, but seems to be
a significant improvement over previously reported scintographic
techniques. In our local experience, it has a 90% sensitivity in
detecting an abnormal (enlarged) parathyroid gland, but is less
reliable in actually differentiating an adenoma from hyperplasia.
The local experience in Hawaii confirms published data. Sestamibi
scans overestimates adenoma (sensitivity 95%, PPV 76%) and
underestimates hyperplasia (sensitivity 45%, PPV 100%). There
were two false positives and three false negatives for HPT (in the
literature, false positives tend to occur with thyroid nodules and
false negatives with smaller glands of hyperplasia).5Of the 33
patients in our study, 25 had primary HPT and 8 had secondary HPT
with ESRD. A small subpopulation of 3 patients had previous
thyroid or parathyroid surgery. No ectopic glands occurred in this
study. Adenoma could not be reliably differentiated from hyperpla
sia in the study population.
Despite the excellent results ofthe MIBI scan, it is unclear and still
controversial whether this accuracy can compete with the even
Continued on Page 120
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better success of an experienced surgeon in
initial surgeries for HPT. Some argue preop
erative localization for HPT is probably not
justified. There may, however, be a role for
preoperative localization in patients with re
current HPT and previous parathyroid or thy
roid neck surgery. Controversy aside, MIBI
scan in most cases may still be the best tech
nique in nuclear medicine for detecting abnor
mal parathyroid glands.
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